SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION

[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on November 17, 2015, it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq’s filing requirement set forth in Listing Rule 5250(c)(1) (the “Rule”)] []

By | 2016-03-27T15:01:34+00:00 November 20th, 2015|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] NT 10-Q: (Original Filing)

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: September 30, 2015 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By | 2016-03-28T17:45:44+00:00 November 17th, 2015|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] NT 10-Q: FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER:

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: September 30, 2015 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By | 2016-03-28T17:47:11+00:00 November 17th, 2015|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2015 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 16, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093015.htm]

By | 2016-03-28T19:06:42+00:00 November 16th, 2015|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q: FORM 10-Q (Mark One) x September 30, 2015

[FORM 10-Q (Mark One) x September 30, 2015 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 16, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093015.htm]

By | 2016-03-28T19:07:51+00:00 November 16th, 2015|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Third Quarter Financial Results -- Conference call scheduled for Thursday, November 12, 2015 at 8:00 AM ET -- BEIJING, November 11, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter and nine month financial results for the period ended September 30, 2015. Third Quarter] []

By | 2016-03-16T06:10:31+00:00 November 13th, 2015|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More
Skip to toolbar